--- title: One small nudge for vancomycin dosing, one easy win for AUC target attainment description: Discover how a simple addition to vancomycin dosing software improved AUC target attainment by 1.4% across multiple hospital systems, enhancing patient care. image: https://blog.insight-rx.com/hubfs/AUC%2024%2048%20post.png --- [![InsightRX](https://blog.insight-rx.com/hubfs/insightrx_logo_white-teal.svg)](https://blog.insight-rx.com/) - For Providers - Solutions - [MIPD for Providers Explore our full solution for Bayesian model-informed dosing](https://www.insight-rx.com/mipd) - [Future of Pharmacy Learn what's next for AI in health tech, and why architecture matters](https://www.insight-rx.com/future) - Products - [InsightRX Nova Bayesian dosing (MIPD) app for bedside clinical decision support](https://www.insight-rx.com/provider/nova) - [InsightRX Apollo Real-time clinical analytics to measure outcomes](https://www.insight-rx.com/provider/apollo) - [Drug Modules Available medications for precision dosing apps](https://www.insight-rx.com/provider/drug-modules) - [For Life Sciences](https://www.insight-rx.com/life-sciences) - Overview - [InsightRX for Life Sciences Explore our solution for biopharma and clinical trial use](https://www.insight-rx.com/life-sciences) - Products - [Nova for Life Sciences Precision dosing app for clinical trial use](https://www.insight-rx.com/life-sciences/nova) - [Astra for Life Sciences AI-native environment for PK/PD modeling and simulation](https://www.insight-rx.com/life-sciences/astra) - Platform - [Continuous Learning Patented process for model retraining and improvement](https://www.insight-rx.com/platform/continuous-learning) - [Integrations Platform interoperability setup with EHRs, EDCs, and more](https://www.insight-rx.com/platform/integrations) - [Security & Regulatory Standards for product development and release](https://www.insight-rx.com/platform/security-regulatory) - [Success & Support Pharmacist-led training, onboarding, and education](https://www.insight-rx.com/platform/support) - Resources - Science - [Data Science Explore the science and learn more about our R&D](https://www.insight-rx.com/data-science) - [Scientific Publications Impactful research manuscripts with at least one InsightRX author](https://www.insight-rx.com/data-science/scientific-publications) - [How to Cite Using one of our apps? Follow this easy guide for citation in research](https://www.insight-rx.com/how-to-cite-insightrx-nova) - Explore - [Success Stories Case studies from real InsightRX customers about their journey](https://www.insight-rx.com/success-stories) - [White Papers In-depth analysis and best practices for review and download](https://blog.insight-rx.com/resources/tag/white-papers) - [Pubs. Using InsightRX Review research that has used InsightRX applications](https://www.insight-rx.com/publications-using-insightrx-software) - [Blog](https://blog.insight-rx.com/resources) - [All Blog Posts Read the latest posts by our team of experts](https://blog.insight-rx.com/resources) - [Product Innovation The latest updates on our products, services, and science](https://blog.insight-rx.com/resources?section=product_innovation) - [Thought Leadership Posts from our team of experts on PK, MIPD, science, and more](https://blog.insight-rx.com/resources?section=thought_leadership) - Company - About - [About Us Our story, what drives us and why we're passionate about our work](https://www.insight-rx.com/about) - [Leadership Founders and team leaders who strive toward excellence in MIPD](https://www.insight-rx.com/leadership) - [Advisory Board Scientists and experts to ensure our collective success](https://www.insight-rx.com/advisory-board) - [Careers Interested in joining? View available openings here](https://www.insight-rx.com/careers) - [Customers Hear what others have to say about their experience](https://www.insight-rx.com/customers) - Press - [All Stories InsightRX news, company updates, and more](https://blog.insight-rx.com/press-releases) - [Press Releases Announcements for events, partnerships, and company updates](https://blog.insight-rx.com/press-releases?section=press_releases) - [Media InsightRX in the news — digital, print, podcasts, and other outlets](https://blog.insight-rx.com/press-releases?section=media) [![Contact Us](https://no-cache.hubspot.com/cta/default/40041574/interactive-193831493462.png)](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=AVxigLIVhNAV4frdGw7WK4%2FsUL9BSW7sTFfaUWeB6c0miW6Ak22RBUNE5R8BeaQrWqzDSork53FkrNEqiSn%2FTM4f%2BVzPNcA0Ikxp7y6GqZRUQJ2HulFNF849cXXSebQBDVQXFR3hVvn8tZ3jkxYoygqRgjFUwIOapgI0FM8UFCm2xhxz2SgLhEGqk1U%3D&webInteractiveContentId=193831493462&portalId=40041574) [![Contact Us](https://no-cache.hubspot.com/cta/default/40041574/interactive-193831493462.png)](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=AVxigLIVhNAV4frdGw7WK4%2FsUL9BSW7sTFfaUWeB6c0miW6Ak22RBUNE5R8BeaQrWqzDSork53FkrNEqiSn%2FTM4f%2BVzPNcA0Ikxp7y6GqZRUQJ2HulFNF849cXXSebQBDVQXFR3hVvn8tZ3jkxYoygqRgjFUwIOapgI0FM8UFCm2xhxz2SgLhEGqk1U%3D&webInteractiveContentId=193831493462&portalId=40041574) Thought Leadership # One small nudge for vancomycin dosing, one easy win for AUC target attainment - Published May 28, 2026 By [Dominic Tong](https://blog.insight-rx.com/resources/author/dominic-tong) ![](https://blog.insight-rx.com/hubfs/AUC%2024%2048%20post.png) Vancomycin has a narrow therapeutic index - subtherapeutic exposure is associated with treatment failure and supratherapeutic exposure is linked to acute kidney injury. We experimented with one small nudge in the InsightRX Nova precision dosing software. Across 34 sites that opted in, AUC24 target attainment improved by 1.4%, while no significant improvements were observed at 34 other sites that didn't. ## What we changed Early vancomycin area-under-the-curve over 24 hours (AUC24) target attainment is crucial for treatment efficacy in vancomycin, commonly associated with [better patient outcomes](https://pubmed.ncbi.nlm.nih.gov/32191793/). AUC24 24-48 hours out from the dosing decision time is sometimes low for patients who accumulate vancomycin slowly. To help bring this to our clinical user's attention, we suggested adding the AUC24-48 metric to the dosing advice table, like this: | **Dose** | **Interval** | **Infusion Length** | **AUC24-48** | **AUC24,ss** | | --- | --- | --- | --- | --- | | 750mg | 12 hours | 1 hour | 340 mg·h/L | 402 mg·h/L | | 1000mg | 12 hours | 1 hour | 378 mg·h/L | 455 mg·h/L | | 1250mg | 12 hours | 1 hour | 410 mg·h/L | 503 mg·h/L | **Table 1.** How the dosing advice table for vancomycin looks if you have this feature on! Imagine you are the clinician. When you see this metric, you'll see how AUC is ramping up from one day out (AUC24-48) up to steady state (AUC24, SS). This helps you figure out if you want to change the recommended dose to get to the AUC target of 400-600 mg·h/L [quickly and safely](https://blog.insight-rx.com/resources/vancomycin-auc-trough-correlation). ## How “ITS” evaluated Thanks to the thirty-four hospital systems that made this change with us, we can look at what happened with an interrupted time series (ITS) analysis. ITS is a quasi-experimental method that aims to isolate the impact of a specific intervention in real-world data while other things are also changing. An ITS asks: if we draw a line through the pre-intervention data, and then a line through the post-intervention data, is there a big jump at the intervention point? And do the slopes of the pre- and post-intervention data change? We have previously used an ITS to see how the choice of popPK model impacts patient exposure. We found that another change (switching the default dosing model) [improved vancomycin AUC24 target attainment while holding adverse events steady](https://academic.oup.com/jacamr/article/8/1/dlag016/8488539). We looked at changes in AUC target attainment in the year before and the year after sites added this new column. As a control, we matched these 34 intervention sites with 34 sites that did not implement the new column. The interventions ranged from April 2024 to September 2025. Because there is no intervention date for the control sites by definition, we used the average intervention date of July 1, 2024 as a control. ## Did it actually work? Adding the AUC24-48 metric improved AUC target attainment on day 2 of the treatment course by 1.41% (p = 0.014) and over the whole treatment course by 1.40% (p = 0.005). The control group saw no statistically significant jump in AUC target attainment (AUC day 2: +0.63%, p = 0.353; AUC over the whole treatment course: +0.34%, p = 0.538). While 1.4% seems small, this was also a very small change to the InsightRX Nova software – just adding a column! – and you get one additional patient reaching the target for every 71 patients dosed. ![AUC 24 48 post](https://blog.insight-rx.com/hs-fs/hubfs/AUC%2024%2048%20post.png?width=800&height=533&name=AUC%2024%2048%20post.png) **Figure 1.** Interrupted time series analysis of vancomycin AUC target attainment on day 2 of the treatment course (left) and over the whole treatment course (right) for 34 hospital systems with the AUC24-48 column turned on at week 0 (teal, intervention group) and 34 systems who did not (navy blue, control group). **What this means for you:** one column, 1.4% better target attainment across 34 hospital systems. For a 1000-bed hospital, that's 98 more patients on target per year, (assuming roughly 7 patients/bed/year). Learn about how hospitals and health systems like yours are using InsightRX to improve care at their organizations. [![Explore case studies](https://no-cache.hubspot.com/cta/default/40041574/interactive-213735002714.png)](https://blog.insight-rx.com/hs/cta/wi/redirect?encryptedPayload=AVxigLJC%2BuQiyOF%2Fbwzil8yRDXVGldKzlvX6EbrqpXweDXQiBE7xQFYpdOuczA3EvyhATlavp2%2BG%2FENuj9VQoMr9%2BqtBgFyeyMqr2Sytpz%2B6u1dHDqCLKrylOUQ0k%2B1nXgfhkdpQeD1s2B3J5uEZbNehogsU7Bt5VA%2BgiTahfsyw3i11cfYwLHZgW1b0qkCnrg%3D%3D&webInteractiveContentId=213735002714&portalId=40041574) [vancomycin](https://blog.insight-rx.com/resources/tag/vancomycin) [data science](https://blog.insight-rx.com/resources/tag/data-science) [clinical evidence](https://blog.insight-rx.com/resources/tag/clinical-evidence) #### On this page… About the author [Dominic Tong, PhD](https://blog.insight-rx.com/resources/author/dominic-tong) Principal Data Scientist **Connect with us to get the latest blog updates, instantly sent to your inbox** ## Dig deeper. Explore related articles and additional posts on the InsightRX blog. [Product Innovation Sep 5, 2025 New Continuous Learning PK Model Outperforms Published PopPK Models for Gentamicin](https://blog.insight-rx.com/resources/continuous-learning-approach-gentamicin-precision-dosing) [Product Innovation Jul 16, 2025 Elevating Precision Dosing for Hemodialysis Patients: A New Vancomycin CRRT Model](https://blog.insight-rx.com/resources/new-model-for-vancomycin-patients-on-hemodialysis-improves-predictive-performance) [Thought Leadership Dec 26, 2024 How are pharmacokinetic models selected for InsightRX Nova?](https://blog.insight-rx.com/resources/insightrx-nova-pk-model-selection-process) #### What We Do ##### For Providers - [Nova (Bayesian Dosing)](https://www.insight-rx.com/provider/nova) - [Apollo (Clinical Analytics)](https://www.insight-rx.com/provider/apollo) - [Drug Modules](https://www.insight-rx.com/provider/drug-modules) ##### For Life Sciences - [Nova (MIPD for Clinical Trials)](https://www.insight-rx.com/life-sciences/nova) - [Astra (AI-Powered Clin Pharm)](https://www.insight-rx.com/life-sciences/astra) - [Companion Applications](https://www.insight-rx.com/life-sciences/nova#companion-applications) #### How We Do It ##### Platform - [Continuous Learning](https://www.insight-rx.com/platform/continuous-learning) - [Integrations](https://www.insight-rx.com/platform/integrations) - [Security & Regulatory](https://www.insight-rx.com/platform/security-regulatory) - [Success & Support](https://www.insight-rx.com/platform/success-support) ##### Science - [Data Science](https://www.insight-rx.com/data-science) - [Scientific Publications](https://www.insight-rx.com/data-science/scientific-publications) #### Information ##### Resources - [Success Stories](https://www.insight-rx.com/success-stories) - [White Papers](https://www.insight-rx.com/white-papers) - [Publications Using InsightRX](https://www.insight-rx.com/publications-using-insightrx-software) - [How to Cite InsightRX](https://www.insight-rx.com/how-to-cite-insightrx-nova) ##### Blog - [All Posts](https://blog.insight-rx.com/resources) - [Product Innovation](https://blog.insight-rx.com/resources?section=product_innovation) - [Thought Leadership](https://blog.insight-rx.com/resources?section=thought_leadership) #### About - [Our Story](https://www.insight-rx.com/about) - [Leadership](https://www.insight-rx.com/leadership) - [Advisory Board](https://www.insight-rx.com/advisory-board) - [Our Customers](https://www.insight-rx.com/customers) - [Press Releases](https://blog.insight-rx.com/press-releases?section=press_releases) - [Media](https://blog.insight-rx.com/press-releases?section=media) - [Careers](https://www.insight-rx.com/careers) - [Contact](https://www.insight-rx.com/contact-us) --- ![CE marking](https://blog.insight-rx.com/hubfs/ce-mark-white.svg) InsightRX Nova is HITRUST CSF r2 certified, CE marked, and 21 CFR Part 11 compliant. Our quality management, risk management, software lifecycle, and usability engineering processes conform to ISO 13485, IEC 62304, ISO 14971, IEC 62366-1, and IEC 82304-1. InsightRX Nova is not considered to be a medical device in the U.S. and has not been submitted to the U.S. Food and Drug Administration for review or clearance. 740-05000-REC-01 · 08/2025 --- [![InsightRX](https://blog.insight-rx.com/hubfs/insightrx_logo_white-teal.svg)](https://www.insight-rx.com/) 548 Market Street #88083 San Francisco, CA 94104 --- © 2026 InsightRX, Inc. All rights reserved. [Privacy Policy](https://www.insight-rx.com/privacy-policy) Cookie Preferences ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Dominic Tong, PhD - Principal Data Scientist", "url" : "https://blog.insight-rx.com/resources/author/dominic-tong" }, "dateModified" : "2026-05-28T02:56:36.747Z", "datePublished" : "2026-05-28T02:54:20.000Z", "headline" : "One small nudge for vancomycin dosing, one easy win for AUC target attainment", "image" : [ "https://blog.insight-rx.com/hubfs/AUC%2024%2048%20post.png" ], "mainEntityOfPage" : { "@id" : "https://blog.insight-rx.com/resources/one-easy-win-for-auc-target-attainment", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.insight-rx.com/hubfs/insightrx_logo_color%20500%20x%20250-1.png" }, "name" : "InsightRX" } } ```